To conduct a phase 2 dengue human challenge clinical trial of abviro anti-dengue monoclonal antibody (MAB) AV-1.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00055
- Awardee
-
Abviro LLC UEI K3L6KXJ9B6M7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,335,102
Award facts
- Opportunity
-
- 2022 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20221 · Posted Jan 4, 2022
- Contract value 92% obligated
-
- $11,335,102.00 Current, with exercised options
- $12,356,811.00 Potential, with all options
- Completion date 95% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 31 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Bethesda, MD 20814, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $2,591,663 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $6,235,886 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Funding Only Action | $754,586 | |
| Other Administrative Action | $0 | |
| Original award | $1,752,967 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $12.36 million definitive contract to Abviro LLC on September 25, 2023, to conduct a Phase 2 dengue human challenge clinical trial of the company's anti-dengue monoclonal antibody candidate, AV-1. The contract, which operates under a cost-plus fixed fee pricing structure with no set-aside designation, is scheduled for completion by December 31, 2026, and will be performed in Bethesda, Maryland. This award emerged from a January 2022 NIAID Broad Agency Announcement that solicited proposals for vaccine candidates, therapeutics, and diagnostics addressing biodefense, antimicrobial resistance, and emerging infectious diseases, with fiscal year 2023 funding estimates of up to $12.8 million across vaccine and therapeutic development areas.
The award supports NIAID's mission to develop medical countermeasures against infectious disease threats, positioning the Phase 2 clinical trial within the agency's therapeutics development portfolio. Dengue represents a significant public health concern as a mosquito-borne viral infection affecting millions globally, making the advancement of targeted monoclonal antibody therapeutics a priority within the broader antimicrobial resistance and emerging infectious disease research initiatives. The human challenge trial model provides a controlled clinical environment to evaluate AV-1's efficacy and safety profile in advancing toward potential commercialization and public health availability.
Quick answers
Who was awarded contract 75N93023C00055?
75N93023C00055 was awarded to Abviro LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 25, 2023.
How much is contract 75N93023C00055 worth?
The government has obligated $11,335,102 on 75N93023C00055. Its potential value, with all options, is $12,356,811.
Was contract 75N93023C00055 competed?
The extent of competition for 75N93023C00055 was full and open competition. The government received 31 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award